EP1084118A1 - Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4- 4-(4pyridyl) benzoyl] piperazine - Google Patents

Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4- 4-(4pyridyl) benzoyl] piperazine

Info

Publication number
EP1084118A1
EP1084118A1 EP99919395A EP99919395A EP1084118A1 EP 1084118 A1 EP1084118 A1 EP 1084118A1 EP 99919395 A EP99919395 A EP 99919395A EP 99919395 A EP99919395 A EP 99919395A EP 1084118 A1 EP1084118 A1 EP 1084118A1
Authority
EP
European Patent Office
Prior art keywords
chloronaphth
ylsulphonyl
benzoyl
piperazine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99919395A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marianne Ashford
Roger James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1084118A1 publication Critical patent/EP1084118A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • Factor Xa is one of a cascade of proteases involved in the complex process of blood coagulation.
  • the protease known as thrombin is the final 5 protease in the cascade and Factor Xa is the preceding protease which cleaves prothrombin to generate thrombin.
  • a Compound of the invention refers to either one of features (a), (b) or (c) described above. 5
  • reduced particle size we refer to solid Compound 1, or a pharmaceutically-acceptable salt thereof, or a solvate of either thereof, reduced by suitable processing techniques to a solid of smaller particle size and, consequently, greater surface area. Any number of processing techniques known in the pharmaceutical field may be used to reduce solid particle size, such as grinding, milling and micronising, reference should be made 10 to Remington: The Science and Practise of Pharmacy, 19 th Ed., pages 1598-1602, for a more exhaustive review.
  • a powder of which not less than 90% by weight of the particles pass through a sieve with a nominal mesh aperture of 45 ⁇ m.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
EP99919395A 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4- 4-(4pyridyl) benzoyl] piperazine Withdrawn EP1084118A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9809350.3A GB9809350D0 (en) 1998-05-02 1998-05-02 Novel salt
GB9809350 1998-05-02
PCT/GB1999/001316 WO1999057112A1 (en) 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine

Publications (1)

Publication Number Publication Date
EP1084118A1 true EP1084118A1 (en) 2001-03-21

Family

ID=10831311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99919395A Withdrawn EP1084118A1 (en) 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4- 4-(4pyridyl) benzoyl] piperazine

Country Status (16)

Country Link
EP (1) EP1084118A1 (no)
JP (1) JP2002513789A (no)
KR (1) KR20010043216A (no)
CN (1) CN1308629A (no)
AU (1) AU3719699A (no)
BR (1) BR9910176A (no)
CA (1) CA2331041A1 (no)
EE (1) EE200000638A (no)
GB (1) GB9809350D0 (no)
HU (1) HUP0102394A3 (no)
IL (1) IL139405A0 (no)
NO (1) NO20005498D0 (no)
PL (1) PL343705A1 (no)
SK (1) SK16522000A3 (no)
WO (1) WO1999057112A1 (no)
ZA (1) ZA200006036B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255733T3 (es) * 1997-09-30 2006-07-01 Daiichi Pharmaceutical Co., Ltd. Derivados sulfonilo.
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
ATE334975T1 (de) * 1997-05-30 2006-08-15 Takeda Pharmaceutical Sulfonamidderivate, ihre herstellung und verwendung
ES2255733T3 (es) * 1997-09-30 2006-07-01 Daiichi Pharmaceutical Co., Ltd. Derivados sulfonilo.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9957112A1 *

Also Published As

Publication number Publication date
KR20010043216A (ko) 2001-05-25
EE200000638A (et) 2002-04-15
ZA200006036B (en) 2002-01-25
NO20005498L (no) 2000-11-01
WO1999057112A1 (en) 1999-11-11
HUP0102394A3 (en) 2003-01-28
CN1308629A (zh) 2001-08-15
BR9910176A (pt) 2001-01-09
IL139405A0 (en) 2001-11-25
GB9809350D0 (en) 1998-07-01
PL343705A1 (en) 2001-08-27
HUP0102394A2 (hu) 2001-12-28
SK16522000A3 (sk) 2001-05-10
JP2002513789A (ja) 2002-05-14
AU3719699A (en) 1999-11-23
CA2331041A1 (en) 1999-11-11
NO20005498D0 (no) 2000-11-01

Similar Documents

Publication Publication Date Title
US6022869A (en) Aminoheterocyclic compounds with antithrombotic/anticoagulant effect
EP1477175B1 (en) Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
US6458793B1 (en) Heterocyclic derivatives which inhibit factor Xa
TWI232105B (en) Novel compounds and their preparation process and pharmaceutical formulation containing the same
TW200402416A (en) Novel piperidine derivatives
EP2138482A1 (en) Bicyclic heterocyclic compound
AU733093B2 (en) Cyanoguanidines as cell proliferation inhibitors
EP1015449B1 (en) (hetero)aryl-sulfonamide derivatives, their preparation and their use as factor xa inhibitors
JP4248245B2 (ja) 6−フェニルベンゾナフチリジン
JP2023518356A (ja) Covid-19関連状態の治療のための方法
EP1084118A1 (en) Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4- 4-(4pyridyl) benzoyl] piperazine
AU757738B2 (en) Heterocyclic derivatives as inhibitors of Factor Xa
WO2001017990A1 (en) Heterocyclic derivatives as inhibitors of factor xa
JP2007532626A (ja) Hiv治療用硫黄連結イミダゾール化合物
MXPA00010676A (en) Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl]piperazine
WO2006077497A1 (en) Crystalline forms cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido) cyclohexyl]-2-(tetrahydrothiopyran-a-yloxy) nicotinamide
CZ20004037A3 (cs) Forma l-(6-chlornaft-2-ylsulfonyl)-4-[4-(4- pyridyl)benzoyl]piperazinu se zmenšenu velikostí částic a farmaceutická kompozice tuto formu obsahující
WO2000078749A1 (en) Sulfonamide derivative as factor xa inhibitor
EP1683795A1 (en) Crystalline forms of cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide
MXPA01008067A (es) Derivados heterociclicos como inhibidores del factor xa
JPH0378864B2 (no)
MXPA00000505A (en) Heterocyclic derivatives which inhibit factor xa

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001204;LT PAYMENT 20001204;LV PAYMENT 20001204;MK PAYMENT 20001204;RO PAYMENT 20001204;SI PAYMENT 20001204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031101

RTI1 Title (correction)

Free format text: REDUCED PARTICLE SIZE FORM OF 1-(6-CHLORONAPHTH-2- YLSULPHONYL) -4- 4-(4PYRIDYL) BENZOYL PIPERAZINE

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036620

Country of ref document: HK